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models of human non-small cell lung cancer is augmented by 
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Background: VEGF is a prime driver of endothelial cell survival, pro-
liferation and migration in the tumor vasculature. In addition, preclini-
cal evidence points to a role of FGF and PDGF in tumour angiogenesis, 
mediated by endothelial and smooth muscle cells and pericytes. The 
indolinone kinase inhibitor, BIBF 1120, concomitantly blocks VEGFR, 
FGFR and PDGFR signaling at low nM concentrations in vitro and 
affects tumor vasculature in xenograft models, as shown by DCE-MRI. 
BIBF 1120, with its unique triple angiokinase proﬁle, has demonstrated 
encouraging results in phase I clinical trials in cancer patients and is 
now in phase II combination studies. 
Methods: The human NSCLC models H460 and Calu-6 were used to 
evaluate the antitumor effects of BIBF 1120 in combination with tax-
anes and pemetrexed. Cell proliferation, apoptosis, and survival were 
analysed in cultured tumor cells and endothelial cells (HUVEC). In 
vivo xenografts growing s.c. in nude mice were treated with suboptimal 
doses of either BIBF 1120 (25 mg/kg daily p.o.), taxotere (7.5 mg/kg 
once weekly i.v.) or pemetrexed (100 or 150 mg/kg qdx5 i.p.), alone or 
in combination. TUNEL staining of frozen tumor sections was used to 
determine the fraction of apoptotic tumor cells.
Results: In vitro proliferation of VEGF-stimulated HUVEC was 
inhibited by BIBF 1120 (24% inhibition at 10 nM) and paclitaxel alone 
(17% at 1 nM), with additive effects (92%) seen with the combina-
tion. In parallel, the fraction of apoptotic cells increased from ~25% in 
cultures treated with BIBF 1120 or paclitaxel alone to ~50% in cultures 
treated with the combination. The proliferation of H460 NSCLC cells 
in vitro was poorly inhibited even at high concentrations of BIBF 1120 
alone (10% at 1 µM), compared to 10 nM paclitaxel alone (42%) or 
the respective combination (94% inhibition). In vivo studies with the 
NSCLC models revealed that combination of BIBF 1120 with docetax-
el in H460 xenografts has clear antitumor efﬁcacy with a T/C ratio of 
27% at dose levels where the single-agent treatments had no or little ef-
ﬁcacy (T/C 75% and 66%, resp.). Similarly, BIBF 1120 in combination 
with pemetrexed in Calu-6 xenografts resulted in additive antitumor 
activity (T/C 23%) compared with single-agent treatment (T/C 37% 
and 42%, resp.). The enhanced in vivo efﬁcacy was accompanied by an 
increase in tumor cell apoptosis detected by immunohistochemistry.
Conclusions: Combining BIBF 1120 with paclitaxel has a marked 
impact on the proliferation and survival of tumor and endothelial cells 
in vitro. Combinations of BIBF 1120 with docetaxel or pemetrexed 
show improved antitumor activity in vivo compared to single-agent 
treatment. These results lend support to further clinical studies of BIBF 
1120 in combination with established chemotherapeutic agents.
C7-04 Tumor & Cell Biology, Wed, 10:30 - 12:15
Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR 
and HER2 in human NSCLC xenografts and in a transgenic mouse 
lung-cancer model
Shimamura, Takeshi1 Greulich, Heidi1,2 Solca, Flavio F.3 Wong, Kwok-
Kin1 
1 Dana Farber Cancer Institute, Boston, MA, USA 2 Broad Institute of 
MIT and Harvard, Boston, MA, USA 3 Boehringer-Ingelheim, Vienna, 
Austria 
Background: Geﬁtinib (Iressa) and erlotinib (Tarceva) are both selec-
tive and reversible inhibitors of the epidermal growth factor receptor 
(EGFR) tyrosine kinase. In clinical trials, both compounds showed 
efﬁcacy speciﬁcally in NSCLC patients. Several EGFR mutations as-
sociated with clinical response to Iressa or Tarceva have been identiﬁed 
in patients with NSCLC. These include complex in-frame deletions 
in exon 19 mainly covering the ELREA amino acid sequence or point 
mutations within exon 21 (e.g. L858R). However, many responding 
patients develop clinical resistance and relapse. In the majority of 
cases, the molecular basis for resistance seems to be the acquisition of a 
secondary T790M point mutation in the kinase domain of EGFR. This 
bulky amino acid substitution most likely weakens the binding of both 
reversible inhibitors. By contrast, BIBW 2992, currently in clinical 
development, is an irreversible, dual EGFR/HER2 inhibitor. BIBW 
2992 has demonstrated encouraging results in phase I with 3 objective 
responses in NSCLC patients, 2 harboring EGFR-del-19 mutations. 
The present study investigates BIBW 2992 in tumor models with the 
EGFR L858R/T790M double mutation.
Methods: To assess the proﬁle of BIBW 2992 on various mutants of 
the human EGFR we generated stable clones of Ba/F3 cells expressing 
the EGFR-L858R mutant, or various exon 19 deletion mutants, alone 
or in combination with the T790M resistance mutation. Drug sensitivity 
was assessed in standard MTT assays. The in vivo efﬁcacy of BIBW 
2992 on NSCLC tumors carrying the EGFR-L858R/T790M mutation 
was evaluated in nude mice bearing human NSCLC xenografts as well 
as in a transgenic mouse model. Mice were treated orally once daily 
with BIBW 2992 at 15 or 20 mg/kg. Tumor growth and body weights 
were monitored 3 times a week.
Results: BIBW 2992 displayed potent inhibitory activity in all cell 
lines carrying EGFR mutants, including those with the T790M resis-
tance mutation. As expected, erlotinib and geﬁtinib were active in all 
exon 19 deletion mutants but failed to inhibit the proliferation of Ba/F3 
cells carrying the T790M mutation. In vivo, BIBW 2992 induced long-
lasting growth suppression in the H1975 xenograft model which carries 
the EGFR-L858R/T790M mutation. The T/C values (treated/control) 
at the end of the experiment were 12% and 18 % at 15 and 20 mg/kg/d 
respectively. Reversible inhibitors such as lapatinib or geﬁtinib did 
not display any anti-tumor activity in this model suggesting that the 
irreversible binding of BIBW 2992 is key to its activity in these mutant 
cells. Furthermore, the efﬁcacy of BIBW 2992 was conﬁrmed in a 
transgenic mouse model based on tetracycline-inducible expression of 
EGFR-L858R/T790M in pneumocytes. Treatment of mice with estab-
lished tumor burden with BIBW 2992 resulted in tumor regressions. 
Treatment was well tolerated by the animals during all experiments. 
Conclusion: The orally bioavailable, irreversible and dual EGFR/
HER2 inhibitor BIBW 2992 shows efﬁcacy in multiple human NSCLC 
models. Our data support further clinical investigation of BIBW 2992 
in NSCLC patients harboring sensitizing as well as resistance muta-
tions.
